Elyssa Margolis

Elyssa Margolis

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
LFLloyd D. Fricker
Lloyd D. Fricker
EMElyssa Margolis
Elyssa Margolis
IGIvone Gomes
Ivone Gomes
LDLakshmi Devi
Lakshmi Devi
In the mid-1970s, an intense race to identify endogenous substances that activated the same receptors as opiates resulted in the identification of the first endogenous opioid peptides. Since then, >20 peptides with opioid receptor activity have been discovered, all of which are generated from three precursors, proenkephalin, prodynorphin, and proopiomelanocortin, by sequential proteolytic processing by prohormone convertases and carboxypeptidase E. Each of these peptides binds to all three of the opioid receptor types (μ, δ, or κ), albeit with differing affinities. Peptides derived from proenkephalin and prodynorphin are broadly distributed in the brain, and mRNA encoding all three precursors are highly expressed in some peripheral tissues. Various approaches have been used to explore the functions of the opioid peptides in specific behaviors and brain circuits. These methods include directly administering the peptides ex vivo (i.e., to excised tissue) or in vivo (in animals), using antagonists of opioid receptors to infer endogenous peptide activity, and genetic knockout of opioid peptide precursors. Collectively, these studies add to our current understanding of the function of endogenous opioids, especially when similar results are found using different approaches. We briefly review the history of identification of opioid peptides, highlight the major findings, address several myths that are widely accepted but not supported by recent data, and discuss unanswered questions and future directions for research. SIGNIFICANCE STATEMENT Activation of the opioid receptors by opiates and synthetic drugs leads to central and peripheral biological effects, including analgesia and respiratory depression, but these may not be the primary functions of the endogenous opioid peptides. Instead, the opioid peptides play complex and overlapping roles in a variety of systems, including reward pathways, and an important direction for research is the delineation of the role of individual peptides.

29 October 2014 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EMElyssa Margolis
Elyssa Margolis
GHGregory O. Hjelmstad
Gregory O. Hjelmstad
WFWakako Fujita
Wakako Fujita
HFHoward L. Fields
Howard L. Fields
The ventral tegmental area (VTA) is required for the rewarding and motivational actions of opioids and activation of dopamine neurons has been implicated in these effects. The canonical model posits that opioid activation of VTA dopamine neurons is indirect, through inhibition of GABAergic inputs. However, VTA dopamine neurons also express postsynaptic μ-opioid peptide (MOP) receptors. We report here that in Sprague Dawley rat, the MOP receptor-selective agonist DAMGO (0.5–3 μm) depolarized or increased the firing rate of 87 of 451 VTA neurons (including 22 of 110 dopamine neurons). This DAMGO excitation occurs in the presence of GABAAreceptor blockade and its EC50value is two orders of magnitude lower than for presynaptic inhibition of GABA release on to VTA neurons. Consistent with a postsynaptic channel opening, excitations were accompanied by a decrease in input resistance. Excitations were blocked by CdCl2(100 μm,n= 5) and ω-agatoxin-IVA (100 nm,n= 3), nonselective and Cav2.1 Ca2+channel blockers, respectively. DAMGO also produced a postsynaptic inhibition in 233 of 451 VTA neurons, including 45 of 110 dopamine neurons. The mean reversal potential of the inhibitory current was −78 ± 7 mV and inhibitions were blocked by the K+channel blocker BaCl2(100 μm,n= 7). Blockade of either excitation or inhibition unmasked the opposite effect, suggesting that MOP receptors activate concurrent postsynaptic excitatory and inhibitory processes in most VTA neurons. These results provide a novel direct mechanism for MOP receptor control of VTA dopamine neurons.

4 November 2018 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
JBJocelyn Breton
Jocelyn Breton
ACAnnabelle R. Charbit
Annabelle R. Charbit
BSBenjamin J. Snyder
Benjamin J. Snyder
PFPeter T. K. Fong
Peter T. K. Fong
EDElayne V. Dias
Elayne V. Dias
EMElyssa Margolis
Elyssa Margolis

18 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EMElyssa Margolis
Elyssa Margolis
HFHoward L Fields
Howard L Fields
Increased activity of lateral habenula (LHb) neurons is correlated with aversive states including pain, opioid abstinence, rodent models of depression, and failure to receive a predicted reward. Agonists at the mu opioid receptor (MOR) are among the most powerful rewarding and pain relieving drugs. Injection of the MOR agonist morphine directly into the habenula produces analgesia, raising the possibility that MOR acts locally within the LHb. Consequently, we examined the synaptic actions of MOR agonists in the LHb using whole cell patch clamp recording. We found that the MOR selective agonist DAMGO inhibits a subset of LHb neurons both directly and by inhibiting glutamate release onto these cells. Paradoxically, DAMGO also presynaptically inhibited GABA release onto most LHb neurons. The behavioral effect of MOR activation will thus depend upon both the level of intrinsic neuronal activity in the LHb and the balance of activity in glutamate and GABA inputs to different LHb neuronal populations.

1 October 2019 in Neurochemistry International
Verified
Journal Article
Closed access
EMElyssa Margolis
Elyssa Margolis
Anushree KarkhanisAnushree Karkhanis
Anushree Karkhanis

1 September 2017 in Neuropharmacology
Verified
Journal Article
Closed access
EMElyssa Margolis
Elyssa Margolis
WFWakako Fujita
Wakako Fujita
LDLakshmi A. Devi
Lakshmi A. Devi
HFHoward L. Fields
Howard L. Fields